TY - JOUR
T1 - Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance
AU - Hu, Yunwen
AU - Lu, Shuihua
AU - Song, Zhigang
AU - Wang, Wei
AU - Hao, Pei
AU - Li, Jianhua
AU - Zhang, Xiaonan
AU - Yen, Hui-Ling
AU - Shi, Bisheng
AU - Li, Tao
AU - Guan, Wencai
AU - Xu, Lei
AU - Liu, Yi
AU - Wang, Sen
AU - Zhang, Xiaoling
AU - Tian, Di
AU - Zhu, Zhaoqin
AU - He, Jing
AU - Huang, Kai
AU - Chen, Huijie
AU - Zheng, Lulu
AU - Li, Xuan
AU - Ping, Jie
AU - Kang, Bin
AU - Xi, Xiuhong
AU - Zha, Lijun
AU - Li, Yixue
AU - Zhang, Zhiyong
AU - Peiris, Malik
AU - Yuan, Zhenghong
N1 - Copyright © 2013 Elsevier Ltd. All rights reserved.
PY - 2013/6/29
Y1 - 2013/6/29
N2 - BACKGROUND: On March 30, a novel influenza A subtype H7N9 virus (A/H7N9) was detected in patients with severe respiratory disease in eastern China. Virological factors associated with a poor clinical outcome for this virus remain unclear. We quantified the viral load and analysed antiviral resistance mutations in specimens from patients with A/H7N9.METHODS: We studied 14 patients with A/H7N9 disease admitted to the Shanghai Public Health Clinical Centre (SPHCC), China, between April 4, and April 20, 2013, who were given antiviral treatment (oseltamivir or peramivir) for less than 2 days before admission. We investigated the viral load in throat, stool, serum, and urine specimens obtained sequentially from these patients. We also sequenced viral RNA from these specimens to study the mutations associated with resistance to neuraminidase inhibitors and their association with disease outcome.FINDINGS: All patients developed pneumonia, seven of them required mechanical ventilation, and three of them further deteriorated to become dependent on extracorporeal membrane oxygenation (ECMO), two of whom died. Antiviral treatment was associated with a reduction of viral load in throat swab specimens in 11 surviving patients. Three patients with persistently high viral load in the throat in spite of antiviral therapy became ECMO dependent. An Arg292Lys mutation in the virus neuraminidase (NA) gene known to confer resistance to both zanamivir and oseltamivir was identified in two of these patients, both also received corticosteroid treatment. In one of them, wild-type sequence Arg292 was noted 2 days after start of antiviral treatment, and the resistant mutant Lys292 dominated 9 days after start of treatment.INTERPRETATION: Reduction of viral load following antiviral treatment correlated with improved outcome. Emergence of NA Arg292Lys mutation in two patients who also received corticosteroid treatment led to treatment failure and a poor clinical outcome. The emergence of antiviral resistance in A/H7N9 viruses, especially in patients receiving corticosteroid therapy, is concerning, needs to be closely monitored, and considered in pandemic preparedness planning.FUNDING: National Megaprojects of China for Infectious Diseases, Shanghai Municipal Health and Family Planning Commission, the National Key Basic Research Program of China, Ministry of Science and Technology, and National Natural Science Foundation of China.
AB - BACKGROUND: On March 30, a novel influenza A subtype H7N9 virus (A/H7N9) was detected in patients with severe respiratory disease in eastern China. Virological factors associated with a poor clinical outcome for this virus remain unclear. We quantified the viral load and analysed antiviral resistance mutations in specimens from patients with A/H7N9.METHODS: We studied 14 patients with A/H7N9 disease admitted to the Shanghai Public Health Clinical Centre (SPHCC), China, between April 4, and April 20, 2013, who were given antiviral treatment (oseltamivir or peramivir) for less than 2 days before admission. We investigated the viral load in throat, stool, serum, and urine specimens obtained sequentially from these patients. We also sequenced viral RNA from these specimens to study the mutations associated with resistance to neuraminidase inhibitors and their association with disease outcome.FINDINGS: All patients developed pneumonia, seven of them required mechanical ventilation, and three of them further deteriorated to become dependent on extracorporeal membrane oxygenation (ECMO), two of whom died. Antiviral treatment was associated with a reduction of viral load in throat swab specimens in 11 surviving patients. Three patients with persistently high viral load in the throat in spite of antiviral therapy became ECMO dependent. An Arg292Lys mutation in the virus neuraminidase (NA) gene known to confer resistance to both zanamivir and oseltamivir was identified in two of these patients, both also received corticosteroid treatment. In one of them, wild-type sequence Arg292 was noted 2 days after start of antiviral treatment, and the resistant mutant Lys292 dominated 9 days after start of treatment.INTERPRETATION: Reduction of viral load following antiviral treatment correlated with improved outcome. Emergence of NA Arg292Lys mutation in two patients who also received corticosteroid treatment led to treatment failure and a poor clinical outcome. The emergence of antiviral resistance in A/H7N9 viruses, especially in patients receiving corticosteroid therapy, is concerning, needs to be closely monitored, and considered in pandemic preparedness planning.FUNDING: National Megaprojects of China for Infectious Diseases, Shanghai Municipal Health and Family Planning Commission, the National Key Basic Research Program of China, Ministry of Science and Technology, and National Natural Science Foundation of China.
KW - Acids, Carbocyclic
KW - Aged
KW - Aged, 80 and over
KW - Antiviral Agents/therapeutic use
KW - Base Sequence
KW - China/epidemiology
KW - Cyclopentanes/therapeutic use
KW - Drug Resistance, Viral
KW - Female
KW - Guanidines/therapeutic use
KW - Humans
KW - Influenza A virus/drug effects
KW - Influenza, Human/drug therapy
KW - Male
KW - Middle Aged
KW - Molecular Sequence Data
KW - Oseltamivir/therapeutic use
KW - RNA, Viral/genetics
KW - Virus Shedding
U2 - 10.1016/S0140-6736(13)61125-3
DO - 10.1016/S0140-6736(13)61125-3
M3 - Article
C2 - 23726392
SN - 0140-6736
VL - 381
SP - 2273
EP - 2279
JO - Lancet
JF - Lancet
IS - 9885
ER -